Starbucks stock has risen just 1.5% this year, giving the company a market value of $115 billion.
Continue readingCategory Archives: Uncategorized
Shares of e.l.f Beauty surge 15% after company raises full-year guidance on surging sales
Drugstore makeup brand e.l.f Beauty raised its full year outlook after reporting a 76% sales jump as the red-hot beauty market continues to surge.
Continue readingVirgin Galactic banks $2 million in quarterly revenue after first commercial spaceflight
Virgin Galactic flew two spaceflights during the second quarter: Its final test spaceflight and its first commercial spaceflight.
Continue readingTiger Woods joins PGA Tour board as Saudi deal talks continue
Superstar Tiger Woods is joining the PGA Tour board after former AT&T chief Randall Stephenson resigned citing “serious concerns” regarding the Saudi deal.
Continue readingTrump-endorsed ‘Sound of Freedom’ has outgrossed ‘Mission: Impossible,’ ‘The Flash’
Angel Studios’ “Sound of Freedom” has generated nearly $150 million at the domestic box office since its early July debut, topping some Hollywood heavyweights.
Continue readingAs the new Bed Bath & Beyond launches, here’s what shoppers can expect
Bed Bath & Beyond relaunched as an online-only retailer after Overstock won its intellectual property at auction.
Continue readingFord restarts F-150 Lightning production, says demand jumped sixfold after July price cuts
Ford’s Rouge Electric Vehicle Center will be able to produce Lightnings at an annual rate of 150,000 vehicles, three times its previous output.
Continue readingCVS to slash 5,000 jobs as company deepens costly health-care push
The pharmacy chain had about 300,000 employees in the U.S. at the end of last year, according to a securities filing.
Continue readingMerck beats on revenue boosted by Keytruda sales, but posts quarterly loss due to Prometheus deal
Shares of Merck are down roughly 4% this year, with a market value of roughly $270 billion, making it the third largest pharmaceutical company based […]
Continue readingPfizer beats on earnings, but revenue misses as Covid product sales plummet
Pfizer is in a transition period as it pivots away from its blockbuster Covid vaccine and drug Paxlovid while the world emerges from the pandemic.
Continue reading